FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Novo Nordisk and Eli Lilly are reducing prices for their widely used obesity medications, Wegovy and Mounjaro, in China, a move that could significantly expand patient access in one of the world’s largest pharmaceutical markets. The price adjustment comes as China faces steadily rising obesity rates and growing demand for effective weight-loss treatments.
Novo Nordisk confirmed that it has begun adjusting the prices of Wegovy in China, although the company did not disclose a full breakdown of the new pricing structure. According to Chinese business news outlet Yicai, list prices for the two highest dosages of Wegovy have been reduced by as much as 48% in certain provinces. Under the reported changes, the monthly cost for these dosages has fallen to approximately 987 yuan ($141) and 1,284 yuan ($183), marking a substantial decrease compared with previous pricing.
In a statement, Novo Nordisk said the price reduction is aimed at easing the financial burden on patients and improving overall treatment accessibility. The company emphasized that the pricing adjustment aligns with its broader commitment to addressing chronic diseases such as obesity and supporting better long-term health outcomes for patients.
Chinese drug suppliers have also indicated that Eli Lilly’s obesity treatment, Mounjaro, is seeing similar price adjustments, although detailed figures have not been officially confirmed. Both Wegovy and Mounjaro are part of a new generation of GLP-1-based medications that have gained global attention for their effectiveness in weight management and metabolic health.
The price cuts could have a meaningful impact in China, where obesity and related conditions such as type 2 diabetes and cardiovascular disease are becoming more prevalent due to lifestyle changes and urbanization. Lower prices may encourage more patients to seek medical treatment rather than relying solely on diet or unregulated supplements.
For Novo Nordisk and Eli Lilly, reducing prices in China may also help strengthen their competitive positions as domestic pharmaceutical companies accelerate development of similar weight-loss drugs. Overall, the move highlights how global drugmakers are adapting pricing strategies to local markets while responding to rising demand for obesity treatments worldwide.
